Volume : 09, Issue : 12, December – 2022
Title:
48.DEVELOPMENT AND VALIDATION OF A RP – HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF AZELNIDIPINE AND CHLORTHALIDONE IN PURE AND PHARMACEUTICAL DOSAGE FORM
Authors :
P.Priyanka, Shyamala, J.V.C Sharma
Abstract :
Analytical Method Development and Validation for Azelnidipine and Chlorthalidone in bulk and Combined Dosage Form by RP-HPLC. New method was established for simultaneous estimation of Azelnidipine and Chlorthalidone by RP-HPLC method. The chromatographic conditions were successfully developed for the separation of Azelnidipine and Chlorthalidone by using Inertsil C18 (4.6mm ×250mm, 5µm particle size), flow rate was 1.0 ml/min, mobile phase ratio was (55:45% v/v) Methanol: Phosphate buffer pH 4.8 (pH was adjusted with ortho phosphoricacid), detection wavelength was 282nm. The instrument used was WATERS Alliance 2695 separation module, Software: Empower 2, 996 PDA detector. The retention times were found to be 1.688mins and 3.282mins. The % purity of Azelnidipine and Chlorthalidone was found to be 99.86%. The system suitability parameters for Azelnidipine and Chlorthalidone such as theoretical plates and tailing factor were found to be 7586, 1.69 and 6235 and 1.58, the resolution was found to be 10.85. The analytical method was validated according to ICH guidelines (ICH, Q2 (R1)). The linearity study of Azelnidipine and Chlorthalidone was found in concentration range of 100µg-500µg and 30µg-70µg and correlation coefficient (r2) was found to be 0.999 and 0.999, % recovery was found to be 100.112% and 100.16%, %RSD for repeatability was 0.1702 and 0.043 respectively. The precision study was precise, robust, and repeatable. The LOD value was found to be 2.1µg/ml and 1.28µg/ml, and LOQ value was 6.3µg/ml and 3.84µg/ml for Azelnidipine and Chlorthalidone respectively. Hence the suggested RP-HPLC method can be used for routine analysis of Azelnidipine and Chlorthalidone in API and Pharmaceutical dosage form.
Keywords: Azelnidipine and Chlorthalidone, Method Development, Validation, Accuracy, Precision.
Cite This Article:
Please cite this article in press P.Priyanka et al, Development And Validation Of A Rp – Hplc Method For The Simultaneous Determination Of Azelnidipine And Chlorthalidone In Pure And Pharmaceutical Dosage Form.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
2. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients
3. Wright JM, Lee CH, Chambers GK: Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? CMAJ. 1999 Jul 13;161(1):25-32
4. Siragy HM: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Curr Hypertens Rep. 2003 Aug;5(4):293-4. [Article]
5. Pranali V. Dhasade1 , SagarS. Kale, Manoj S. Patil, Swati S. Agawane, Shital P. Gaikwad. Development and Validation of an Analytical Method for Simultaneous EstimationofAzelnidipine and Chlorthalidone by UV in Fixed -Dose Combination. International Journal of Pharmaceutical Research and Applications Volume 7, Issue 4 July-Aug 2022, pp: 1265-1275
6. Silky Agrawal, Tahir Nizami. Method development and validation for the simultaneous determination of azelnidipine and telmisartan in tablet dosage form by rp- hplc. International Journal of Pharmaceutical Sciences and Medicine. 2021:6(10);26-36
7. Aher, S. S., R. B. Saudagar, and H. Kothari. “Development and validation of rp-hplc method for simultaneous estimation of azilsartan medoxomil and chlorthalidone in bulk and tablet dosage form”. International Journal of Current Pharmaceutical Research, vol. 10, no. 6, Nov. 2018, pp. 21-24.
8. Nirma Chavda, Suresh Kumar. A Review article on Analytical Method Development for the combination of Azelnidipine and Telmisartan. Asian Journal of Pharmaceutical Analysis. 2021; 11(3):227-4.
9. Rlc, Sasidhar & Vidyadhara, S. & Deepti, B. & Tejaswi, K. & Suhasini, J.. (2014). Development and Validation of Rp – Hplc Method for the Simultaneous Determination of Hydrochlorothiazide, Amlodipine Besylate and Telmisartan in Bulk and Pharmaceutical Formulation. Oriental Journal of Chemistry. 30. 1815-1822.
10. Jayvadan, Patel. (2014). Validated Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Azelnidipine and Olmesartan in Their Combined Dosage Form. Scientia Pharmaceutica. 82. 541-554.
11. Solanki VS, BISHNOI R, Baghel R, Jain D. RP-HPLC method development and validation for simultaneous estimation of Cilnidipine, Atenolol and Chlorthalidone. JDDT [Internet]. 15Dec.2018 [cited 6Sep.2022];8(6-s):78-2.
12. Sohni, S. K., R. Kumar, M. Akhtar, C. Ranjan, and G. Chawla. “Development and validation of rp-hplc method for simultaneous estimation of azilsartan medoximil and chlorthalidone in bulk form and formulation using quality by design”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 2, Feb. 2016, pp. 266-72
13. Rele R.V., Patil S.P.. Ultra-Violet Spectrophotometric Method for Estimation of Azelnidipine from Bulk Drug and Pharmaceutical Formulation. Asian J. Research Chem. 3(4): Oct. – Dec. 2010; Page 1077-1079.